DNA RNA and Cells

17 Oct 2022 Decibel Therapeutics Receives FDA Clearance of IND Application for DB-OTO, a Gene Therapy Product Candidate Designed to Provide Hearing to Individuals with Otoferlin-Related Hearing Loss
17 Oct 2022 Gracell Biotechnologies Doses First Patient in Phase 2 Portion of Registrational Phase 1/2 Clinical Trial Evaluating GC007g for Treatment of B-cell Acute Lymphoblastic Leukemia
14 Oct 2022 Editas Medicine Presents Preclinical Data on EDIT-103 for Rhodopsin-associated Autosomal Dominant Retinitis Pigmentosa at the European Society of Gene and Cell Therapy Annual Meeting
14 Oct 2022 Smart Immune and Greater Paris University Hospitals (AP-HP) begin groundbreaking Phase I/II trial with ProTcellTM, a thymus-empowered T-cell therapy platform, in adults with blood cancers
13 Oct 2022 Dyne Therapeutics Presents Preclinical Data from its Duchenne Muscular Dystrophy Programs Targeting Exons 51 and 53 at World Muscle Society 2022 Congress
13 Oct 2022 FDA Accepts BioMarin's Biologics License Application (BLA) for Valoctocogene Roxaparvovec AAV Gene Therapy for Adults with Severe Hemophilia A
12 Oct 2022 TeraImmune Receives FDA IND Clearance to Initiate Phase 1/2a Clinical Trial of TI-168 for Treatment of Hemophilia A with Refractory Inhibitors
12 Oct 2022 GentiBio Announces Preclinical Data Showing Antigen Specific Engineered Tregs Suppressing Pancreatic Inflammation and Potential Utility for Treatment and Prevention of Clinical Type 1 Diabetes (T1D)
12 Oct 2022 Caring Cross Announces Dosing of First Participant in Anti-HIV DuoCAR-T Cell Therapy Phase 1/2a Clinical Trial
11 Oct 2022 Immatics Reports Interim Clinical Data Update on ACTengine® IMA203 TCR-T Monotherapy Targeting PRAME
07 Oct 2022 Allogene Therapeutics Initiates Industry’s First Allogeneic CAR T Phase 2 Trial
07 Oct 2022 Mustang Bio Announces First Patient Treated in Its Multicenter Phase 1/2 Clinical Trial of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy to Treat B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
05 Oct 2022 Oncternal Therapeutics Receives IND Clearance for ONCT-808, its autologous CAR T Product Candidate Targeting ROR1 for the Treatment of Aggressive B Cell Lymphoma
04 Oct 2022 Atsena Therapeutics Announces Positive Results from Phase I/II Clinical Trial of ATSN-101 for the Treatment of GUCY2D-associated Leber Congenital Amaurosis (LCA1)
03 Oct 2022 Late-Breaking Phase 1/2 Data Demonstrates Safety Profile of Investigational Gene Therapy Botaretigene Sparoparvovec (AAV-RPGR) and Sustained Vision Improvement in Patients with X-Linked Retinitis Pigmentosa (XLRP)
01 Oct 2022 Janssen Announces Late-Breaking Data from Two Gene Therapy Programs at the American Academy of Ophthalmology 2022 Annual Meeting
30 Sep 2022 Rocket Pharmaceuticals Announces Positive Updates from Phase 1 Clinical Trial for RP-A501 in Danon Disease at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022
30 Sep 2022 BioMarin Resubmits Biologics License Application (BLA) for Valoctocogene Roxaparvovec AAV Gene Therapy for Severe Hemophilia A to the FDA
30 Sep 2022 Silence Therapeutics Announces Preliminary Single Dose Results from SLN124 Phase 1 Study in Patients with Thalassemia
29 Sep 2022 gavo-cel Continues to Demonstrate Clinical Benefit in Solid Tumors with Additional RECIST Reponses in Ovarian Cancer and Mesothelioma
28 Sep 2022 Aura Biosciences Announces First Patient Dosed in Phase 1 Study Evaluating Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder Cancer
27 Sep 2022 Immunotherapy: Tollys presents new data at OTS 2022, demonstrating anti-tumor activity of TL-532
27 Sep 2022 Atamyo Therapeutics Announces First Patient Dosed with ATA-100 Gene Therapy in LGMD-R9 Clinical Trial
26 Sep 2022 CellOrigin Biotech Announces Global Strategic Collaboration with Qilu Pharma to Develop "Off-the-Shelf" CAR-iMAC Cell Therapy
26 Sep 2022 Pfizer and Sangamo therapeutics announce phase 3 trial of investigational gene therapy for hemophilia a has re-opened recruitment

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2021 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up